Tarsus Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 25, 2026, details the results of Tarsus Pharmaceuticals, Inc.'s Annual Meeting of Stockholders. The meeting was held on June 25, 2026, with a record date of April 27, 2026. At the record date, the Company had 43,023,959 shares of common stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
A quorum was established with 38,237,214 shares present. Three proposals were submitted and approved:
- Director Elections: Four Class III directors were elected to serve until the 2029 annual meeting.
- Wendy Yarno, MBA: 34,398,690 votes for.
- Andrew Goldberg, M.D.: 26,733,789 votes for (notable withhold votes of 8,039,857).
- Scott Morrison: 34,225,471 votes for.
- David E.I. Pyott, MBA: 33,612,963 votes for.
- Executive Compensation: Stockholders approved the advisory vote on named executive officer compensation with 34,486,767 votes for and 238,014 votes against.
- Auditor Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 38,219,521 votes for and 3,651 votes against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on business outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of the Annual Meeting vote tallies.
Investor Verification Checklist
- Verify the specific reasons for the high number of withheld votes (8,039,857) for director nominee Andrew Goldberg, M.D., compared to other nominees.
- Confirm the composition of the full Board of Directors, including the continuing terms of Bobak Azamian, Katherine Goodrich, Bhaskar Chaudhuri, and William Link.
- Review the definitive proxy statement filed on April 28, 2026, for detailed executive compensation data referenced in the advisory vote.